Treatment of anatomical and functional retinal atrophy
By administering steroids after anti-VEGF treatment, the problem of ineffective or reduced efficacy of retinal eye disorders against VEGF treatment was solved, the treatment effect was improved and the side effects such as insufficient blood supply in vascular system were alleviated, and alternative treatments for retinal diseases were provided.
Patent Information
- Application Number
- CN202380025844.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-15
- Filing Date
- 2023-02-15
- Publication Date
- 2024-11-26
AI Technical Summary
Existing anti-VEGF treatments are not effective for certain retinal eye conditions such as macular degeneration and diabetic macular edema, especially after long-term use, which may lead to insufficient blood supply and retinal atrophy, and some patients do not respond to anti-VEGF drugs or The reaction is gradually lost.
Following anti-VEGF treatment, a therapeutically effective amount of a steroid, such as mineralocorticosterone or glucocorticoid, is administered to treat refractory retinal eye conditions by modulating steroid receptor activity.
Improves the therapeutic effect of retinopathy and provides an alternative to ineffective or reduced efficacy against VEGF treatment, delays the progression of the disease and alleviates related disadvantages.
Smart Images

Figure BDA0005030401070000151 
Figure BDA0005030401070000152 
Figure BDA0005030401070000161
Abstract
Description
Technical Field
[0001] The present invention relates to the field of treating one or more ophthalmic conditions using one or more therapeutic compounds when one or more other forms of treatment are ineffective, no longer effective or have reduced efficacy.
[0002] In one form, the invention involves the administration of one or more therapeutic compounds to treat one or more retinal ocular disorders that are refractory to one or more other therapies.
[0003] In a particular aspect, the invention is useful for treating one or more retinal ocular disorders that are refractory to one or more anti-VEGF therapies.
[0004] The present invention will conveniently be described below in conjunction with age-related macular degeneration (AMD) and diabetic macular edema (DME), however, it will be appreciated that the present invention is not limited to these diseases but relates to a variety of conditions that affect the retina of the eye and which are typically treated with anti-VEGF drugs. Background Art
[0005] It should be understood that any discussion of documents, devices, acts or knowledge in this specification is intended to explain the context of the invention. Furthermore, the discussion throughout this specification stems from the inventor's knowledge and / or the inventor's identification of certain relevant technical problems. Furthermore, any discussion of materials such as documents, devices, acts or knowledge in this specification is intended to explain the background of the invention according to the knowledge and experience of the inventor, and therefore, any such discussion should not be taken as an admission that any material formed part of the prior art base or common general knowledge in the relevant art in Australia or elsewhere on or before the priority date of the disclosure and claims herein.
[0006] Vascular endothelial growth factor (VEGF) is a signaling protein produced by cells that stimulates the formation of new blood vessels in the embryonic circulatory system (angiogenesis) as well as the growth of blood vessels in existing vessels such as after injury (angiogenesis).
[0007] VEGF exerts its biological effects by interacting with transmembrane receptors such as tyrosine kinase receptors VEGFR1 and VEGFR2. The ligands that specifically bind to VEGFR1 are VEGF-A, -B and P1GF, while the ligands that bind to VEGFR2 are VEGF-A, -C, -D and -E.
[0008] However, overexpression of VEGF can lead to vascular disease, including disease in the retina of the eye. Excessive VEGF production can cause retinal damage by: Increased permeability of existing blood vessels, causing them to leak fluid and protein into the retina, causing edema of the surrounding tissue; and Stimulates the growth of new blood vessels within the retina and extending outward from the retina to the surface of the vitreous and also into the space between the retina and the choroid, usually just below the retinal pigment epithelium.
[0009] Anti-VEGF therapies block VEGF. They can slow the growth of blood vessels in the eye and are widely used to treat certain retinal diseases, such as: Macular degeneration (MD), particularly neovascular age-related macular degeneration (wet AMD), involves abnormal overgrowth of blood vessels from the choroid to the retina that can leak exudate and fluid; Swelling of the retina, called macular edema (ME), including angiographic cystoid macular edema, diabetic macular edema (DME), and cystoid macular edema (CME), usually caused by disease (such as diabetes), injury, or eye surgery; diabetic retinopathy (DR), in which abnormal new blood vessels form in the back of the eye as part of proliferative diabetic retinopathy (PDR) and may break and bleed; and • Retinal vein occlusions, such as central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO), are usually caused by thrombosis.
[0010] For example, first-line anti-VEGF therapy for neovascular AMD includes intravitreal injection of the humanized monoclonal antibody bevacizumab (Avastin TM ) and ranibizumab (Ranibizumab, Lucentis TM ) and the recombinant fusion protein Aflibercept (Aflibercept, Eylea TM ).
[0011] In recent years, research has begun to investigate combination therapies with the goal of dual-targeting inhibition of VEGR-A and VEGR-C / -D. An example of this type of potential treatment is OPT-302 (sVEGFR-3), a "trap" inhibitor of VEGF-C and VEGF-D developed by Opthea Limited that can be used in combination with any existing anti-VEGF-A drug, biosimilar, or new therapy in development for wet AMD and DME.
[0012] Several studies have been conducted to investigate the potential link between macular atrophy (MA) of the retinal pigment epithelium (RPE) and anti-VEGF therapy in patients with AMD. A review article by Horani et al. considered the various clinical studies on MA and stated that "when considering the numbers and results of all relevant studies, when expressing the percentage of the total study eyes evaluated as of the mean follow-up, the mean percentage of eyes without baseline MA was 80% and the median was 89%. The mean percentage of MA incidence was 29%, which was also the median. The mean prevalence of MA at the end of the study was 50% and the median was 46%. The number of study eyes included in the studies that were treated and continued to be followed up until the end of the mean follow-up period ranged from 28 to 1024 eyes, with a median of 118 eyes and a mean cohort size of 242 eyes." (Mania Horani, Sajjad Mahmood, Tariq M. Aslam (2020) A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. Ophthalmology and Therapy 9:35-75). Geographic atrophy (GA)
[0013] GA is an eye disease that can lead to severe vision loss and affects approximately five million people worldwide.
[0014] According to reports, the American Academy of Ophthalmology (AAO) Analysis of clinical data from the IRIS (Intelligent Research in Vision) registry showed that more than 69,000 GA patients experienced significant disease progression over a two-year period, highlighting the urgent need for treatment (C. Francois and E. Rahimy (2020) New Findings from the IRIS Registry: Evaluating Geographic Atrophy in Real-world Clinical Practice presented at American Academy of Ophthalmology (AAO) 2020 Conference).
[0015] It has also been reported that the likelihood of developing new onset of wet age-related macular degeneration (AMD) in GA eyes is almost three times higher when wet AMD is already detected in the fellow eye (ibid.).
[0016] It was reported that during the first 12 months, 4.7% of patients with bilateral GA (GA in both eyes) and 13.3% of patients with wet AMD in the fellow eye progressed from GA to new-onset wet AMD, while at 24 months the incidence of bilateral GA and wet AMD in the fellow eye was 8.2% and 21.6%, respectively (ibid.). Neovascular AMD
[0017] Anti-VEGF drugs have significant effects in treating eye diseases. However, some subjects do not respond to anti-VEGF drugs, respond poorly, or lose their efficacy after repeated administration of anti-VEGF drugs over time.
[0018] For example, patients with neovascular AMD are treated with anti-VEGF drugs until they are completely "dry," meaning there is no fluid in the space under the area. If the fluid comes back or vision worsens, treatment can be resumed with the same anti-VEGF drug, but the condition may not respond. Some patients who receive anti-VEGF treatment become dry initially, but then begin to accumulate fluid again.
[0019] Intravitreal anti-VEGF injections for AMD cannot be used indefinitely to treat diseases like AMD because they prevent all blood vessel growth. The main risk of macular degeneration is vascular insufficiency, and long-term use of anti-VEGF therapy can create more vascular insufficiency. Further use of anti-VEGF drugs can lead to a further increase in the risk of vascular insufficiency.
[0020] Outer retinal atrophy (cRORA) is a type of RPE atrophy that may be associated with long-term anti-VEGF treatment for AMD. Clinically, this atrophy manifests as bare spots in the fundus, which can be identified by methods such as Cirrus spectral domain optical coherence tomography (SD-OCT) imaging. The number of anti-VEGF injections has been shown to be inversely correlated with cRORA area and growth. (Complete RPE and Outer Retinal Atrophy in Patients Receiving anti-VEGF Treatment for Neovascular Age-related Macular Degeneration, Eng et al, PLoS One 2020; 15(5)Ie0232353, 5May 2020) Diabetic retinopathy
[0021] Macular degeneration occurs primarily through damage to the outer retinal and choroidal blood vessels, whereas diabetic retinopathy occurs primarily through damage to the inner retinal blood vessels. In the proliferative form of diabetic retinopathy, VEGF is thought to be responsible for driving the angiogenesis process.
[0022] Anti-VEGF drugs are an emerging treatment for PDR (and potentially non-proliferative DR) and may initially lead to regression of PDR by reducing terminal neovascularization caused by ischemia. Intravitreal injection of anti-VEGF drugs may also be associated with increased fibrosis and regression of the vascular component of fibrovascular proliferation, leading to retinal detachment. (A. Fung & M. Hui, PDR: A New Anti-VEGF Era?, Miophthalmology, 10 July 2018)
[0023] Therefore, there is a continuing need for alternative treatments for diseases affecting the retina of the eye. Summary of the invention
[0024] It is an object of the present invention to provide an alternative treatment for retinal disorders when existing treatments have not achieved the desired effect or no longer provide the desired effect.
[0025] It is another object of the present invention to alleviate at least one of the disadvantages associated with the prior art.
[0026] It is an object of the embodiments described herein to overcome or mitigate at least one of the above-mentioned disadvantages of related art systems, or to at least provide a useful alternative to related art systems.
[0027] In a first aspect of the embodiments described herein, a method of treating a subject having a retinal ocular disorder refractory to anti-VEGF treatment is provided, the method comprising administering to the subject a therapeutically effective amount of one or more steroids, preferably one or more mineralocorticoids or glucocorticoids, following anti-VEGF treatment, thereby treating the retinal ocular disorder.
[0028] In a second aspect of the embodiments described herein, a method of treating a subject having a retinal ocular disorder that is refractory to anti-VEGF treatment is provided, the method comprising administering to the subject a therapeutically effective amount of one or more compounds capable of modulating the activity of a steroid receptor (preferably a glucocorticoid receptor and / or a mineralocorticoid receptor) following anti-VEGF treatment, thereby treating the retinal ocular disorder.
[0029] In a third aspect of the embodiments described herein, a method of treating a subject having a retinal ocular disorder refractory to anti-VEGF treatment is provided, the method comprising administering to the individual, following anti-VEGF treatment, at a concentration and dosage sufficient to improve the retinal ocular disorder: (a) a therapeutically acceptable steroid formulation suitable for delivery to the eye, and (b) at least one second therapeutically active compound.
[0030] In particularly preferred embodiments of any of the above aspects of the invention, the steroid is one or more mineralocorticoids or glucocorticoids or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof.
[0031] The one or more mineralocorticoids or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof may include one or more of the following: 11-desoxycortisone (11-DC); fludrocortisone; fludrocortisone acetate (FA); fludrocortisone acetonide; deoxycorticosterone acetate (DA); deoxycorticosterone (DS); or aldosterone; or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof.
[0032] The one or more glucocorticoids or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof may include one or more of the following: Cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, beclomethasone, fluocinolone or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof.
[0033] The one or more mineralocorticoids and / or one or more glucocorticoids or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof may comprise one or more dual-acting compounds, wherein each dual-acting compound is capable of modulating the activity of both a mineralocorticoid receptor and a glucocorticoid receptor.
[0034] The dual-acting compound may comprise one or more of the following: triamcinolone; triamcinolone acetonide; cortisol; cortisone; prednisone; prednisolone; methylprednisolone; fludrocortisone; fludrocortisone acetate; fludrocortisone acetonide; or a therapeutically active analog, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof.
[0035] In a particularly preferred embodiment, one or more mineralocorticoids or one or more glucocorticoids or their therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates include fludrocortisone or its therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates. Its therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates may include one or more of fludrocortisone acetate and fludrocortisone acetonide.
[0036] In a specific embodiment, the one or more mineralocorticoids and / or one or more glucocorticoids or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof include triamcinolone acetonide or a therapeutically active analog, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof.
[0037] In particularly preferred embodiments of any of the above aspects of the invention, the retinal eye disorder is macular edema (ME), such as diabetic macular edema (DME), or age-related macular degeneration (AMD), including wet AMD or dry AMD.
[0038] As used herein, the term "refractory / refractory" when used to describe retinal eye disorders refers to those that do not respond, respond poorly, respond poorly, or lose response over time to anti-VEGF therapy. At any time during anti-VEGF treatment, an eye disorder may become refractory and may fail from the outset, or become less effective or even harmful to the subject after an initially successful treatment period. Such eye disorders may become refractory to treatment due to a variety of factors, including continued activation of other pathogenic pathways, rapid tolerance, pharmacodynamic tolerance, changes in the structure of the neovascularization, redundant or compensatory angiogenic factors, continued activation of the complement system and inflammatory response, and genetic factors.
[0039] As used herein, the term "ocular disorder" includes any ocular disorder, such as an early or subclinical stage ocular disease that has proven refractory to anti-VEGR therapy.
[0040] According to any of the above aspects, the retinal eye disorder may be: an exudative eye disorder; a posterior ocular disorder; macular degeneration, including age-related macular degeneration (AMD), including dry (geographic atrophy) and wet (choroidal neovascularization (CNV)); macular edema (ME), including diabetic macular edema (DME), angiographic cystoid macular edema, cystoid macular edema (CMO); diabetic retinopathy (DR), including proliferative diabetic retinopathy (PDR); and retinal vein occlusion, including central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO); maculopathy, including age-related maculopathy (ARM); exudative eye diseases or disorders; retinal pigment epithelial detachment (PED); various forms of age-related macular degeneration; diabetic eye diseases or disorders, including diabetic retinopathy; corneal neovascularization; cyclitis; Hippel-Lindel disease (Hippel-Lindel disease disease); retinopathy of prematurity (also known as retrolental fibroplasia); pterygium; histoplasmosis; iris neovascularization; glaucoma; glaucoma-associated neovascularization; Purtcher's retinopathy; intraocular hypertension; macular edema; Coats' disease; uveitis (including anterior uveitis); Sicca syndrome; hereditary diseases associated with increased extracellular lipid storage / accumulation; juvenile macular degeneration; ocular allergies and ocular tumors. Ocular tumors may include retinoblastoma and / or melanoma.
[0041] Ocular diseases or conditions may include posterior ocular diseases or conditions, including exudative posterior ocular exudative diseases or conditions. Posterior ocular diseases or conditions may include ocular diseases or conditions involving the retina, macula and / or fovea of the posterior ocular region. Examples of posterior ocular diseases include macular edema, such as clinical macular edema or angiographic cystoid macular edema caused by various causes (such as diabetes), macular edema and exudative macular degeneration caused by retinal laser treatment, retinal ischemia and choroidal neovascularization, retinal diseases, inflammatory diseases, tumor-related uveitis, such as retinoblastoma or pseudoglioma, neovascularization after vitrectomy, vascular diseases and optic nerve neovascularization. Retinal diseases may be one or more of diabetic retinopathy, diabetic retinopathy, retinal detachment, age-related macular degeneration caused by subretinal neovascularization, and myopic retinopathy. Vascular disease may be one or more of retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, and neovascular retinopathy caused by carotid ischemia.
[0042] In one embodiment of any of the above forms, the ocular disease or disorder comprises dry AMD. Dry AMD can include early AMD and geographic atrophy (GA), which is distinct from exudative AMD.
[0043] The invention may be applied to exudative eye diseases and / or conditions, exudative eye diseases and / or conditions at the back of the eye, age-related macular degeneration, wet age-related macular degeneration, diabetic macular edema (DME), cystoid macular edema (CMO); maculopathy; and / or ocular tumors. Ocular tumors may include retinoblastoma and / or melanoma. The eye disease and / or condition may be a diabetic eye disease and / or condition. Other eye diseases and / or conditions include (non-infectious) conjunctivitis, anterior uveitis and ocular allergies.
[0044] According to any of the above aspects, the eye disease and / or disorder may be a diabetic eye disease and / or disorder.
[0045] In the methods of the present invention, an effective amount of the target compound is preferably used. For formulations, the concentration of the therapeutic compound can be in the range of about 0.01 wt % to about 10 wt %. Typically, the concentration is in the range of 0.025 wt % to about 2.5 wt %.
[0046] As used herein, the phrase "therapeutically effective amount" refers to an amount of a therapeutic compound, alone or in combination with one or more other compounds, sufficient to produce a therapeutic effect on one or more retinal eye disorders. This phrase should not be construed to mean that administration must completely eradicate the retinal eye disorder. What constitutes a therapeutically effective amount will vary depending on the circumstances, particularly the biopharmacological properties of the compound used, the retinal eye disorder being treated, the frequency of administration, the mode of delivery, the characteristics of the subject being treated, the severity of the retinal eye disorder, and the response of the subject. These are the types of factors that one skilled in the art will be aware of and able to consider when formulating a composition for treatment as described herein.
[0047] The present invention may be used in medical or veterinary applications. A "subject" for treatment according to the present invention is a vertebrate, preferably a human.
[0048] In one embodiment of any of the above aspects, one or more steroids are injected into the eye. The injection may comprise a suprachoroidal injection.
[0049] In another embodiment of any of the above aspects, one or more steroids are provided in a unit dose formulation. The unit dose formulation can be provided in a pre-filled syringe. The pre-filled syringe may contain two barrels. The first barrel may contain one or more steroids. A second barrel different from the first barrel may contain one or more additional drugs.
[0050] In another embodiment of any of the above aspects, one or more pharmaceutically acceptable carriers, diluents or excipients may be included, such as one or more surfactants or wetting agents. The surfactant may include polysorbate. The polysorbate may include one or more of polysorbate 20 and polysorbate 80. In a specific embodiment, the surfactant includes polysorbate 80. The pharmaceutically acceptable carrier, diluent or excipient may include carboxymethyl cellulose (CMC).
[0051] In one embodiment of any of the above aspects, the one or more steroids further comprise one or more of a pH adjusting composition and water for injection. The pH adjusting composition may comprise hydrochloric acid and / or sodium hydroxide.
[0052] In another embodiment of any of the above aspects, the one or more steroids have a pH of 6 to 8. The pH may be 6 to 7.5.
[0053] In one embodiment of any of the above aspects, one or more mineralocorticoids and / or one or more glucocorticoids are contained in a balanced salt solution. The balanced salt solution may include saline and a buffer. The balanced salt solution includes sodium chloride; potassium chloride; calcium chloride (dehydrated); magnesium chloride (hexahydrate); sodium acetate (trihydrate); sodium citrate (dehydrated); hydrochloric acid; one or more of sodium hydroxide and water for injection.
[0054] According to any of the above aspects, one or more steroids may constitute a sustained release composition.
[0055] In specific embodiments of any of the above aspects, the one or more steroids may be sterilized.
[0056] In one embodiment of any of the above aspects, at least one additional drug may be administered.
[0057] According to any of the above forms, one or more pharmaceutically acceptable carriers may include cannabis, cannabis oil, or pharmaceutically effective cannabis or cannabis oil extracts. Cannabis, cannabis oil, or pharmaceutically effective cannabis or cannabis oil extracts may contain cannabinoids. Cannabinoids may include cannabidiol. Cannabis, cannabis oil, or pharmaceutically active cannabis or cannabis oil extracts may contain low tetrahydrocannabinol (THC) cannabis, cannabis oil, or pharmaceutically effective extracts. Cannabis, cannabis oil, or pharmaceutically effective cannabis or cannabis oil extracts may be obtained from wild cannabis (Cannabis Ruderalis). Cannabis, cannabis oil, or pharmaceutically effective cannabis or cannabis oil extracts may include water-soluble dosage forms. Cannabis oil may be extracted from cannabis seeds. Cannabis oil may be cold pressed.
[0058] According to one embodiment of any of the above aspects, the cannabis oil may contain about 80% to 90% balanced Omega fatty acids. That is, the cannabis oil contains Omega 3 (ALA), Omega 6 (LA), Omega 6 (GLA) and Omega 9 (oleic acid), which together may account for 80% to 90% of the cannabis oil composition.
[0059] In another embodiment of any of the above aspects, the cannabis oil may contain about 88% balanced omega fatty acids. That is, every 100 grams of cannabis oil may contain about 88 grams of omega fatty acids.
[0060] In another embodiment of any of the above aspects, the cannabis oil may comprise about 15% to 25% Omega 3 (ALA), about 50% to 60% Omega 6 (LA), about 1% to 5% Omega 6 (GLA), and about 10% to 15% Omega 9 (oleic acid) per 100 grams of cannabis oil.
[0061] In another embodiment of any of the above aspects, each 20 g of cannabis oil may comprise about 1 g to 5 g of Omega 3 (ALA), about 5 g to 15 g of Omega 6 (LA), about 0.2 g to 1 g of Omega 6 (GLA), and about 1 g to 5 g of Omega 9 (oleic acid).
[0062] In some embodiments of any of the above aspects, the cannabis oil can include about 3.5 g of Omega 3 (ALA), about 11.2 g of Omega 6 (LA), about 0.4 g of Omega 6 (GLA), and about 2.5 g of Omega 9 (oleic acid).
[0063] In other embodiments of any of the above forms, the cannabis oil may include about 3.3 g of Omega 3 (ALA), about 10.7 g of Omega 6 (LA), about 0.7 g of Omega 6 (GLA), and about 2.7 g of Omega 9 (oleic acid).
[0064] In other embodiments of any of the above aspects, the ratio of Omega 3 to Omega 6 in the cannabis oil may be between about 1:5.2 and 5:16. The ratio of Omega 3 to Omega 6 in the cannabis oil may be about 3.5:11.6. The ratio of Omega 3 to Omega 6 in the cannabis oil may be 1:3.
[0065] In other embodiments of any of the above aspects, cannabis, cannabis oil or a pharmaceutically effective extract is used or used as a carrier or delivery vehicle for one or more steroids.
[0066] In another embodiment, cannabis, cannabis oil or pharmaceutically effective extracts include forms suitable for oral, intradermal, intramuscular, intraperitoneal, parenteral, intravenous, subcutaneous, intranasal, epidural, sublingual, intracerebral, intravaginal, transdermal (e.g., by patch), rectal, inhalation, transmucosal or local (particularly ear, nose, eye or skin) administration. The pharmaceutical composition can be injectable. Parenteral or injectable forms can include any form suitable for parenteral or injection administration, such as injectable solutions, injectable suspensions, injectable emulsions and injections of forms prepared when used. Preparations for parenteral administration can be aqueous or non-aqueous isotonic sterile solutions or suspensions. Injection forms can be used for intravitreal injection.
[0067] In another specific embodiment of any of the above aspects, the cannabis, cannabis oil or pharmaceutically effective extract is free of preservatives.
[0068] In another specific embodiment of any of the above aspects, the cannabis, cannabis oil or pharmaceutically effective extract is prophylactic.
[0069] In certain embodiments of any of the above forms, the cannabis, cannabis oil or pharmaceutically effective extract is sterilized.
[0070] Further aspects and preferred forms are disclosed in the description and / or defined in the appended claims, forming a part of the description of the invention.
[0071] In essence, embodiments of the present invention arise from the recognition that certain compounds are effective against conditions that are refractory to existing therapies.
[0072] Advantages of the present invention include: Improve the treatment of eye diseases; Increased options for treating eye conditions.
[0073] From the detailed description given below, the further applicable scope of the embodiments of the present invention will become apparent. However, it should be understood that the detailed description and specific examples, although indicating the preferred embodiments of the present invention, are only given by way of illustration, because from this detailed description, those skilled in the art will clearly understand various changes and modifications within the spirit and scope disclosed herein. Brief description of the embodiment
[0074] By referring to the specification and the following non-limiting examples in combination with the accompanying drawings, technicians in the relevant field can better understand the further disclosure, objectives, advantages and aspects of the preferred and other embodiments of the present application, but these embodiments are given in an illustrative manner only and therefore do not limit the disclosure of this article. Example 1
[0075] The efficacy and mechanism of FA and TA in regulating the expression levels of Ccl2, Il-6, and Il-8 in Muller cells and their effects on retinal degeneration in PD models were investigated. Full details of the study are included in the Appendix.
[0076] This study demonstrates novel anti-inflammatory and neuroprotective properties of TA, and more specifically FA, in the treatment of retinal degeneration.
[0077] Data show that FA and TA do not cause toxicity in multiple human retinal cell lines, including photoreceptor-like cells (661W), Muller cells (MIO-M1), and RPE (APRE19). Addition of FA or TA significantly reduced the expression of Ccl2, Il-6, and Il-8 in Muller cells stimulated with Il1b or TNFa, depending on glucocorticoid receptor signaling. Finally, administration of FA improves photoreceptor survival in PD, whereas TA has no significant effect. Example 2
[0078] To evaluate the safety and tolerability of single-dose intravitreal (IVT) injections of 1 mg / 0.1 mL and 2 mg / 0.1 mL fludrocortisone acetate (FCA) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
[0079] Methods: This was a two-part, dose-escalation prospective study. Part 1 involved one participant who was treated with 1 mg / 0.1 ml and monitored for up to 28 days, followed by a safety review board review. Two participants were subsequently treated with the same dose. Part 2 involved one participant who was dosed with 2 mg / 0.1 ml, and monitored for up to 28 days when five additional participants were dosed. All participants were followed up for 6 months after baseline.
[0080] Comprehensive ophthalmologic evaluations, including GA area, best-corrected visual acuity (BCVA), low-light BCVA, and intraocular pressure (IOP), were performed at study visits. Adverse events (AEs) were reported from the first dose of FCA until the end-of-study visit.
[0081] Results: No serious AEs (ocular or systemic) were observed with IVT FCA (1 mg / 0.1 ml or 2 mg / 0.1 ml) in any of the 9 participants. There was no evidence of increased IOP or development of cataracts.
[0082] During follow-up, there was no significant change in either the study eye's BCVA or LL-BCVA (p = 0.28 and 0.38, respectively). The mean GA area increased in the study eye (0.5 mm2, p = 0.003) and fellow eye (0.62 mm2, p = 0.02) over 6 months. The difference between the two eyes was not significant (p = 0.64) and was at the lower end of population norms.
[0083] Conclusions: Intravitreal FCA injection is clinically safe and well tolerated, does not increase IOP, and has a good indication in the growth of GA lesions. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1 The effects of FA and TA on retinal cell viability in vitro are illustrated. The effects of FA (AC) and FA (DF) on cell viability were evaluated using the MTT assay on immortalized human cells derived from Muller glia (MIO-M1), RPE (ARPE-19), and photoreceptors (661W). AC: Compared with the DMSO-only group, the addition of FA had no significant effect on the viability of all evaluated cell lines (P>0.05). The exception was MIO-M1 cells (A), whose viability was slightly reduced at the highest concentration (10ug / uL, P<0.05). DF: The introduction of TA also had no significant effect on the viability of all cell lines (P>0.05), except for MIO-M1 (D) and 661W cells (E), whose viability was slightly reduced at 10ug / uL (P<0.05).
[0085] One-way ANOVA and Tukey's post hoc test were used to determine statistical significance. Results are presented as mean ± SEM.
[0086] Figure 2 The regulation of proinflammatory cytokine expression by FA and TA in vitro was demonstrated. The effects of FA and TA on the induction of Ccl2, Il-6, and Il-8 expression were evaluated after stimulation of MIO-M1 cells with IL-1β (AB) or TNF (CD). AB: After stimulation with IL-1β, MIO-M1 cells showed a significant increase in Ccl2, Il-6, and Il-8 expression (P<0.05). However, when FA was added to the culture medium under IL-1β stimulation (A), the upregulation of Ccl2, Il-6, and Il-8 was suppressed to near baseline levels (P<0.05). A significant decrease in the expression of Ccl2, Il-6, and Il-8 was also observed in the group with the addition of TA (P<0.05). CD: TNF stimulation induced a similar, but less pronounced upregulation of Ccl2, Il-6, and Il-8 in MIO-M1 cells (P<0.05). This effect was also significantly inhibited when FA or TA was added to the culture medium (P<0.05).
[0087] One-way ANOVA and Tukey's post hoc test were used to determine statistical significance. Results are presented as mean ± SEM.
[0088] Figure 3 Contribution of glucocorticoid and mineralocorticoid receptor signaling to the anti-inflammatory effects of FA in vitro The inhibitory effect of FA on the expression of Ccl2, Il-6, and Il-8 in Il-lb-stimulated MIO-M1 cells was further investigated by co-incubation with selective antagonists (AD). AB: The study found that the addition of glucocorticoid receptor antagonist RU486 (A) completely abolished FA-mediated inhibition of Ccl2, Il-6, and Il-8 after IL-b stimulation (P<0.05). However, incubation with mineralocorticoid receptor antagonist RU28318 (B) did not significantly alter the expression of Ccl2, Il-6, and Il-8 compared with MIO-M1 cells treated with Il1b and FA alone (P>0.05). CD: After Il1-b stimulation, incubation with the androgen receptor antagonist PF998425 (C) or the estrogen receptor antagonist ICI182780 (D) did not alter the inhibition of Ccl2, Il-6, and Il-8 by FA (P>0.05).
[0089] Statistical significance was determined using two-way ANOVA and Tukey post hoc test. *Indicates significant change compared to FA+IL-1β. Results are presented as mean ± SEM.
[0090] Figure 4 The neuroprotective properties of FA and TA against retinal cell death in mice after PD are illustrated. The effects of intravitreal injection of FA or TA on photoreceptor degeneration after PD were determined by a combination of OCT segmentation (A), ERG recordings (B), and abundance of apoptotic TUNEL+ photoreceptors (C). AC: ONL measurements quantified from OCT images centered on the lesion area (1-2 / 2-3 mm eccentric to the optic nerve) showed that ONL thickness was significantly preserved in the FA-treated group (C, P < 0.05) compared with the control group (B) after PD. In contrast, there was no significant change in the TA-treated group (P > 0.05). DE: a-wave (D) and b-wave (E) ERG responses were significantly greater in FA-treated mice compared to both control and TA-treated groups (P<0.05). FH: After exposure to PD, mice treated with FA were found to have significantly fewer TUNEL+ photoreceptors than mice treated with vehicle (P<0.05). In contrast, there was no significant change in the number of TUNEL+ photoreceptors in mice treated with TA (P>0.05). Statistical significance was determined using one-way ANOVA (A, F, Tukey post hoc test) or two-way ANOVA (D, E, Tukey post hoc test).
[0091] Scale bar represents 50 μm. GCL (ganglion cell layer); INL (inner nuclear layer); ONL (outer nuclear layer).
[0092] Figure 5 The effects of FA and TA on macrophage infiltration in mice after mouse PD are illustrated. Immunolabeling with IBA1 (BC, green) was used to quantify (A) the infiltration of activated macrophages into the outer retina after PD. AC: A large number of IBA1+ macrophages appeared in the outer retina after PD (A), spatially consistent with the destruction of the ONL and subretinal space (B, arrows). In contrast, the number of IBA1+ cells was significantly reduced in the FA-treated and TA-treated groups compared with the control group, with FA showing the most obvious trend (P<0.0001).
[0093] Statistical significance was determined using one-way ANOVA. Scale bar represents 50 μm. GCL (ganglion cell layer); INL (inner nuclear layer); ONL (outer nuclear layer).
[0094] Figure 6 : Examples of atrophy measured by Heidelberg Region Finder software at (A) baseline multicolor, (B) baseline fluorescein angiography, (C) baseline autofluorescence, (D) baseline Region Finder, (E) month 1, (F) month 2, (G) month 3, and (H) month 6. DETAILED DESCRIPTION
[0095] Accordingly, the present invention provides a method of treating a subject having one or more retinal ocular disorders refractory to anti-VEGF therapy, comprising administering to the subject a therapeutically effective amount of one or more steroids, preferably a mineralocorticoid or a glucocorticoid, following anti-VEGF therapy, thereby treating the one or more retinal ocular disorders.
[0096] Suitable steroids for administration include, but are not limited to, cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, triamcinolone (Aristocort TM 、Kenalog TM ), Betamethasone (Celestone TM ), budesonide, fluormetholone (Flarex TM , Eflone TM ), fluormetholone alcohol (fluormetholonealcohol, FML TM 、FML-Mild TM 、FluorOP TM ), medrysone alcohol (HMSO), loteprednol etabonate (Lotemax TM 、Alrex TM ) and anecortave acetate (Alcon TM ), beclomethasone, fludrocortisone, deoxycorticosterone, aldosterone, triamcinolone acetonide (TA), 11-deoxycorticosterone (11-DC), fludrocortisone (FA), deoxycorticosterone acetate (DA), deoxycorticosterone (DS), fluocinolone acetonide or its therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates. It should be understood that the above list is representative only and not exclusive.
[0097] The therapeutically effective amount of one or more compounds may be capable of modulating the activity of steroid receptors, preferably glucocorticoid receptors and / or mineralocorticoid receptors, following anti-VEGF treatment, thereby treating retinal ocular disorders.
[0098] The one or more compounds may include one or more dual-action compounds, wherein each dual-action compound is capable of modulating the activity of both a mineralocorticoid receptor and a glucocorticoid receptor. The dual-action compound may, for example, comprise one or more of: cortisol, cortisone, prednisone, prednisolone, methylprednisolone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, or a therapeutically active analog, derivative, homologue, pharmaceutically acceptable salt or conjugate thereof. Mineralocorticoids
[0099] In preferred embodiments, one or more mineralocorticoids may include one or more of the following: triamcinolone acetonide (TA); 11-deoxycortisone (11-DC); fludrocortisone (FA); deoxycorticosterone acetate (DA); deoxycorticosterone (DS); or aldosterone; or its therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates. Homologues include molecules with the same chemical type but different fixed increments of atoms or constants. Mineralocorticoids may also include one or more pharmaceutically acceptable carriers, diluents or excipients.
[0100] In particularly preferred embodiments, the mineralocorticoid has the following general structure: in R1 is CH3, CH=O, CH2OH, CR=O, CH2NH2, COCHCH2, NO2, X or CH2X, wherein X is F, Cl, Br; R2 is H, OH, =O, NH2 or CN; R3 is H, CH3 or CH2OH; R4 is H, F or Cl; R5 is H, OH, =O, SH, NH2CN, NO2, CH3, CH2OH, CH=O, X, CH2X, OR, OCOR, OPO(OR)2, =CH2 or CHR, wherein X is F, Cl, Br; R6 is H, CH3, X, wherein X is F, Cl, Br; R7 is H, OH, CH3, alkyl, Ph, X, OCH3, OR, SCOCH3, SCOR, OCOR, CH2OH, CH2X, CH=O, CR=O or NHCOR, wherein X is F, Cl, Br; R8 is H, OH, CH3, CH2CH3, SH, NH2 or X, wherein X is F, Cl, Br; R9 is H, OH, SH, NH2, CH3, CH2CH3 or X, wherein X is F, Cl, Br; R 10 It is H, OH, CH3, CH2CH3, SH, NH2, CH2OH, CH2CH2OH, OR, OCOR, OPO(OR)2, NHCOR, CH=O, X or CH2X, wherein X is F, Cl or Br.
[0101] In particularly preferred embodiments, the mineralocorticoid has the following general structure: in R1 is CH3, CH=O or COCHCH2; R2 is H, OH or =O; R3 is H, CH3 or CH2OH; R4 is H or F; R5, R6 and R7 are H; and R8 is H or OH.
[0102] In particularly preferred embodiments, the mineralocorticoid has the following general structure: in A is O, S, NH, CH2, CHOH, C=O, CHX, CHCH3, CH2CH2, OCH2, SCH2, NHCH2, NRCH2, NCOR, wherein X is F, Cl, Br; B is H, OH, SH, NH2, CH2OH, CH2CH2OH, CH=O, X, CH2X, OR, OCOR, OPO(OR)2, NHCOR, wherein X is F, Cl, Br; R1 is H, CH3, CH=O, CH2OH; R2 is H, F or Cl; R3 is H, CH3 or X, wherein X is F, Cl, Br; R4 is H, OH, CH3, alkyl, Ph, X, OCH3, SH, NH2, OR, SCOCH3, SCOR, OCOR, CH2OH, CH2X, CH=O, CR=O, SR or NHCOR, wherein X is F, Cl, Br; R5 is H, CH3, CH2CH3, OH, SH, NH2 or X, wherein X is F, Cl, Br; R7 is H, OH, SH, NH2, NO2, CH=O, CH3, CO2H, CN, CH2CH3, CH2X or X, wherein X is F, Cl, Br. Glucocorticoids
[0103] In a preferred embodiment, the glucocorticoids may include one or more of the following: cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone (Aristocort TM 、Kenalog TM ), beclomethasone (Celestone TM ), fludrocortisone, deoxycorticosterone, aldosterone, fluocinolone acetonide, or therapeutically active analogs, derivatives, homologs, pharmaceutically acceptable salts or conjugates thereof.
[0104] Homologs include molecules having the same chemical type but differing in fixed increments of atoms or constants.The glucocorticoid may also contain one or more pharmaceutically acceptable carriers, diluents or excipients. preparation
[0105] In the methods of the present invention, an effective amount of the target compound is preferably used. For formulations, the concentration of the therapeutic compound can be in the range of about 0.01 wt % to about 10 wt %. Typically, the concentration is in the range of about 0.025 wt % to about 2.5 wt %.
[0106] The precise pharmaceutical formulation used in the methods of the invention will vary according to broad commercial and scientific standards. The skilled reader will appreciate that the above invention may encompass other pharmaceutical agents.
[0107] For example, the preparation used is preferably prepared using physiological saline solution as a carrier. The pH of the preparation can be maintained at a substantially neutral pH (e.g., about 7.4, in the range of about 6.5 to about 7.4) with a suitable buffer known to those skilled in the art. Any pharmacologically acceptable buffer suitable for eyes can be used, such as tris (tris) or phosphate buffer, acetate buffer, citrate buffer, phosphate buffer or borate buffer. Suitable water-soluble buffers that can be used are sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate.
[0108] These agents may be present in amounts sufficient to maintain the pH of the system. Thus, the buffer may comprise about 5 wt % of the total formulation.
[0109] Any diluent used to prepare a pharmaceutically acceptable formulation may be preferably selected so as not to unduly affect the biological activity of the formulation. Examples of particularly useful diluents for injectable formulations are water, organic or inorganic salt solutions, Ringer's solution, dextrose solution, and Hank's solution.
[0110] In addition, the pharmaceutical preparations used in the method of the present invention may also include additives, such as other buffers, diluents, carriers, adjuvants or excipients.
[0111] For various purposes, other agents can be used in the formulation. These include, for example, preservatives, cosolvents, surfactants, oils, wetting agents, softeners, chelating agents, stabilizers, tension regulators or antioxidants. Water-soluble preservatives that can be used include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, sodium bisulphate, phenylmercuric acetate, phenylmercuric nitrate, ethanol, methyl paraben, polyvinyl alcohol, benzyl alcohol and phenylethyl alcohol. Suitable surfactants can be, for example, Tween 80.
[0112] Other agents that can be used include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methylcellulose, polosamers, carboxymethyl cellulose, hydroxyethyl cellulose, purified water. Tension modifiers such as sodium chloride, potassium chloride, mannitol and glycerol can be included. Antioxidants include, but are not limited to, sodium pyrosulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene. Suppliers, indications, effective doses, dosage forms, contraindications, etc. of the compounds in the formulation are available or known to those skilled in the art.
[0113] These agents may be present individually in an amount of about 0.001 wt % to about 5 wt %, and preferably about 0.01 wt % to about 2.0 wt %. Application
[0114] In practicing the methods of the present invention, pharmaceutically acceptable compounds may be administered to patients by any method of delivering the therapeutic compound to the site of the condition affecting the retina of the eye. Any formulation may be administered by an ocular route, such as topical (extraocular application), subconjunctival, sub-Tenon, intraocular, by ocular implants, or systemic (oral or other parenteral routes). Although other modes of administration may also be effective, the administration of the composition is preferably by intraocular injection.
[0115] In a highly preferred form of the invention, when the compound is administered by intravitreal injection to treat retinal disorders of the eye, the active compound should be as concentrated as possible to minimize the volume injected.
[0116] Preferably, the composition is administered in a unit dosage form suitable for a single administration of a precise dose. For example, the composition of the invention may be provided in the form of a single unit dose in a pre-prepared syringe, ready for administration.
[0117] Solid dispersions of therapeutic compounds as well as dissolved formulations can be used to implement the treatment methods of the present invention. For intraocular formulations, the therapeutic compound is delivered at a sufficiently high concentration to achieve a final concentration in the range of about 0.1 μmol / L to about 10 μmol / L in the target ocular region (such as the posterior chamber for the treatment of retinal diseases). Typically for this mode of delivery, the final concentration of the therapeutic compound is in the range of 0.25 μmol / L to about 5 μmol / L.
[0118] The topical application of the preparation of the present invention can be an ointment, gel or eye drops, or a preparation that gels in situ after contact with the eye or tears outside the eye. For topical administration, the concentration of the therapeutic compound administered may depend on the specific subject, the underlying disease and its severity, the frequency of administration, and other factors known to those skilled in the art. Sample concentrations include, but are not limited to, about 0.5 μg / ml to about 500 μg / ml, more preferably about 1.0 μg / ml to about 100 μg / ml, and even more preferably about 5 μg / ml to about 50 μg / ml.
[0119] The formulations can also be administered in the form of sustained-release preparations with carriers such as microspheres, microcapsules or liposomes as topical ointments or solutions, intravenous solutions or suspensions, or intraocular injections, as known to those skilled in the art.
[0120] Sustained release drug delivery systems can be administered intraocularly to provide sustained release of the formulation over a period of time. For example, a sustained release or extended release delivery system can be provided in the form of an implant.
[0121] FA has been shown to be effective in treating DME and other wet retinal diseases. FA has also been tested in safety studies in geographic atrophy. MA is a consequence of long-term use of anti-VEGF therapy. The aim is to test FA primarily in Eylea and other anti-VEGF-refractory DME, and possibly TA. Appendix (Methods and Results of Example 1) method In vitro experiments
[0122] The immortalized retinal cells used were as follows: MIO-M1 cells (Müller cell derived; Müller1 Moorefields, Institute of Ophthalmology, Dr. A. Limb, Institute of Ophthalmology, University College, UK); ARPE19 (RPE derived; ATCC CRL-2302, American Tissue Culture Collection, VA, USA); and 661W cells (photoreceptor-like derived; kindly provided by Dr Muayyad R. Al-Ubaidi, Department of Cell Biology, University of Oklahoma Health Sciences Centre, Oklahoma City, OK, USA). Cells were authenticated and validated by CellBank Australia. MET trial
[0123] MTT assays were performed using immortalized retinal cell lines MIO-M1, 661W, and ARPE19 to assess cellular metabolic activity based on the availability of NAPDH in the cells. Treatments included exposure to one of FA (10-0.01 μg / μl, provided by Prof. Ben Boyd, Monash University, Australia), TA (10-0.01 μg / μl, Honeywell, USA), and dexamethasone (10-0.0001 μg / μl, Sigma-Aldrich, MO, USA). All corticosteroids used in vitro were dissolved in 20% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, MO, USA) and ultrapure endotoxin 0.1 M PBS (Thermo Fisher Scientific, MA, USA). At the 12-hour time point after the addition of corticosteroids, 10 μl of MTT reagent (Roche, Switzerland) was added to each well. To protect from light, the plates were wrapped in foil and stored in the dark at 37°C, 5.0% CO2 for 4 hours. Bright field Zeiss Axiovert 200 inverted microscope (Carl Zeiss Meditec, Dublin, CA, USA) monitored the cells by observing the formation of insoluble purple formazan precipitate crystals in living cells. Then 100 μl of MTT dissolution solution was added and incubated again for 24 h at 37°C in the dark with 5.0% CO2. The cells were incubated using Tecan 200PRO (Tecan, The MTT assay was quantified by measuring the absorbance at 570 nm. IL-1β and TNF-α stimulation
[0124] IL-1β and TNF-α were applied to MIO-M1 cells to initiate an inflammatory response, thereby testing the anti-inflammatory properties of the selected corticosteroids. As described (Section 2.1.1), MIO-M1 cells were grown in 24-well plates to a cell density of 50,000 cells per well using growth medium and fetal bovine serum. MIO-M1 cells were attacked by 1ng / μl of IL-1β or TNF-α (R&D Systems, Minnesota, USA). The experimental wells were treated with 1μg / μl of FA, TA or dexamethasone. After twelve hours of addition, the growth medium was removed from each well and replaced with 860μl of TRIzol (Thermo Fisher Scientific, Massachusetts, USA), stirred about 20 times, and then placed in a clean 1.5ml Eppendorf tube to extract ribonucleic acid (RNA). Animal handling and housing
[0125] All experiments performed were in accordance with the ARVO statement for the use of animals in ophthalmic and vision research and were approved by the ANU Animal Experimentation Ethics Committee (AEEC, protocol number #A2014 / 56). Postnatal day 60 C57BL / 6J mice were used in this study. Animals were born, raised, and maintained under dim light conditions (5 lux) before photooxidative damage. Optical Coherence Tomography (OCT)
[0126] In vivo cross-sectional and fundus images of the mouse retina were acquired using optical coherence tomography (OCT). Intravitreal injection
[0127] Intravitreal injections were performed on postnatal day 60 C57BL / 6J mice. Treatments consisted of exposure to FA or TA dissolved in a suspension consisting of 0.5% w / v carboxymethylcellulose and 0.4% v / v Tween 80. The final concentration of the drug in the vitreous was estimated to be 1 mg / ml. Photooxidative damage in a mouse paradigm
[0128] Age-matched C57BL / 6J mice (postnatal day 60) were continuously exposed to 100K lux white LED light for 5 days with free access to food and water. During this period, 1% atropine sulfate (minimum 1% atropine sulfate eye drops; Bausch and Lomb, USA) was instilled into both eyes twice a day to dilate the pupils. The animals were then euthanized with carbon dioxide (CO2). Electroretinogram (ERG)
[0129] Electroretinography (ERG) was used to evaluate the retinal functional response of rodents to full-field flash stimulation under scotopic conditions. Using known methods, dimly-reared control animals and photo-oxidatively damaged animals were used.
[0130] Before starting the ERG experiments, animals were dark-adapted overnight. Animals were anesthetized as described previously, and all retinal recordings were performed in a dark room with minimal red light. TUNEL
[0131] Terminal deoxynucleotidyl transferase (Tdt) dUTP nick end labeling (TUNEL) is a well-established technique for detecting apoptotic and necrotic cells. Immunohistochemistry
[0132] The detailed information of primary and secondary antibodies is listed in Table 1 . Table 1: Primary and secondary antibodies used for immunohistochemistry. Quantification of TUNEL and IBA1-positive cells
[0133] The retina was evenly divided into 8 quadrants. Each quadrant was observed using a confocal microscope (LSM 5, Zeiss, Germany) to identify and count TUNEL + and IBA1 + Data were plotted and analyzed using Prism 6 software (GraphPad Software, California, USA). Quantitative real-time polymerase chain reaction
[0134] After RNA purification, cDNA was synthesized using Bioline Tetro kit (Bioline, Australia) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (QRT-PCR) was used to analyze the gene expression changes in animal and cell culture samples. TaqMan hydrolysis probe (Applied Biosystems, USA) and Gene Expression Master Mix (Applied Biosystems, USA) were used. Clean 384-well plates (Applied Biosystems, USA) were used, and each biological sample was duplicated. Each sample was set up with a reaction mixture, including 0.5 μl of cDNA, 4 μl of RNase Free Water, 5 μl of gene expression master mixture (Gene Expression Master Mix) and 0.5 μl of Taqman primer probe (Taqman Primer Probe, ThermoFisher Scientific), as listed in Table 2.5. Each sample was amplified using QuantStudio 12K Flex QRT-PCR machine (Applied Biosystems, USA). GAPDH was used as the reference gene and the comparative cycle threshold (C t ) method (ΔΔC t ), as it is known that its expression does not change after retinal photooxidative damage. Data were analyzed using QuantStudio 12K Flex software (Applied Biosystems, USA). Table 2: TaqMan hydrolysis probes used for qPCR. Statistical analysis, image acquisition, and presentation
[0135] All data were analyzed using Prism 6 software (GraphPad Software, CA, USA). Analyses included one-way analysis of variance (ANOVA) and unpaired Student's t test, with appropriate post hoc tests. Results are presented as standard error of the mean. P < 0.05 was considered statistically significant. All images were taken using an A1 Nikon confocal microscope (Nikon, Tokyo, Japan). Images were acquired using NIS-Elements AR software (Nikon, Tokyo, Japan) and uniformly processed using Photoshop CS6 (Adobe Systems, CA, USA). result Cytotoxicity of corticosteroids on retinal cells
[0136] The effects of FA and TA on the viability of MIO-M1, 661W, and ARPE19 cells showed that 1 μg / μl did not significantly alter the cell viability of these cell lines by MTT assay ( Figure 1 , P<0.05). Therefore, all subsequent experiments were performed using this dose of FA and TA, respectively. FA and TA regulate the expression of chemokines and cytokines
[0137] When stimulated by the pro-inflammatory stimulant IL-1β, the gene expression of three key inflammatory markers, CCL2, IL-6, and IL-8, in MIO-M1 cells was significantly increased ( Figure 2 , P<0.05). Figure 2 The results show that the response of MIO-M1 cells to IL-1β stimulation resulted in upregulation of CCL2, IL-6, and IL-8 gene expression. FA treatment restored the gene expression levels of CCL2, IL-6, and IL-8 to baseline levels ( Figure 2 A, P<0.05). Similar levels of CCL2, IL-6, and IL-8 were upregulated in MIO-M1 cells after stimulation with TNF-α, whereas these levels were significantly reduced after treatment with FA ( Figure 2 C, P<0.05).
[0138] Treatment of stimulated cells with TA significantly reduced the expression of CCL2, IL-6, and IL-8 to about one-third of the stimulated level (only IL-1β) ( Figure 2 B, P < 0.05). When TNF-α was used as a proinflammatory stimulus, a similar response pattern was observed for CCL2, IL-6, and IL-8 gene expression, and the gene expression levels of selected inflammatory markers also decreased significantly after the addition of TA ( Figure 2 D, P<0.05). FA regulates the expression of chemokines and cytokines through the mifepristone / (RU486)-sensitive glucocorticoid receptor
[0139] Inclusion of receptor blockers revealed that the effects of FA on target gene expression were offset in the presence of the glucocorticoid receptor blocker mifepristone (RU486), but not in the presence of RU28318 (MR blocker), PF998425 (androgen blocker), or ICI182780 (estrogen blocker) ( Figure 3 ). The results showed that the effect of FA on the expression of CCL2, IL-6, and IL-8 was mediated through the glucocorticoid receptor. This pattern was also observed with TA. FA is a protective and anti-inflammatory agent in a PD model of retinal degeneration
[0140] Compared with the control group, TUNEL expression in the outer retina of mice injected with suspension + FA at 5 days of PD + The number of cells was significantly reduced, which was different from that of mice injected with only suspension and suspension + TA (P < 0.05, Figure 4 A) Compared with the control group, the IBA1 + The number of cells in the mice injected with the suspension vehicle was significantly reduced (P<0.05), but this was not the case in the mice injected with the suspension vehicle only ( Figure 4 B). Compared with the control group, the ONL thickness ratios of mice injected with suspension + FA were significantly greater at 1-2 mm and 2-3 mm above the optic nerve (P<0.05, Figure 4 C), this difference can be detected by OCT ( Figure 4 DG). This effect was not observed in animals injected with suspension + TA. Figure 4 HO. ERG analysis showed that mice injected intravitreally with suspension + FA had significantly increased a-wave and b-wave responses 5 days after PD (P>0.05). The ERG responses of mice injected with suspension alone or suspension + TA were no different from those of PD control / untreated animals ( Figure 4 PQ). There were no significant differences in cone responses between the experimental groups ( Figure 5 .4R).
[0141] Overall, key endpoints investigated include photoreceptor cell death, microglia / macrophage recruitment, ONL thickness, and retinal function, which will help evaluate the efficacy of corticosteroids after PD. Appendix (Methods and Results of Example 2)
[0142] Age-related macular degeneration (AMD) is the leading cause of severe vision loss in people over 65 years of age in Western countries (1). In the United States, approximately 1.75 million people have advanced AMD (2, 3). Early symptoms of AMD (drusen and pigmentary changes) are common in people over 65 years of age and precede the appearance of advanced symptoms that cause severe visual impairment. Advanced AMD symptoms are classified as choroidal neovascularization (wet or exudative) or geographic atrophy (dry).
[0143] Geographic atrophy (GA) is a disease characterized by thinning and loss of the retinal pigment epithelium (RPE), as well as atrophy of photoreceptors and choriocapillaris (4). Clinically, GA is characterized by the presence of a large, progressively enlarging mass of dead retinal cells at the back of the eye. Although GA can cause profound visual impairment in reading, night vision, and dark adaptation, and produce dense, irreversible scotomas in the visual field, the initial decline in VA may be relatively limited if the fovea is preserved. Once the fovea is affected, GA rapidly leads to blindness. GA accounts for approximately 20% of all legal cases of blindness in North America, and its incidence and prevalence are increasing due to longer life expectancy (5).
[0144] AMD is a highly complex disease that is influenced by multiple factors, such as aging, genetic susceptibility, environmental factors, oxidative stress, and inflammation (2, 6, 7). Smoking, age, alcohol consumption, diet, and obesity are important risk factors associated with oxidative stress (7, 8). High body mass index, cardiovascular disease, hypertension, and various dietary patterns are less consistent risk factors (9). Several single nucleotide polymorphisms (SNPs) have been found to increase or decrease the risk of inflammation. They include the well-known complement factor H (CFH), CX3CR1, Toll-like receptor 3 (TLR3), TLR4, and interleukin 8 (IL-8) (10).
[0145] Although AMD is not a classic inflammatory disease, inflammatory cells play an important role in the pathogenesis and progression of AMD (6, 11, 12). Evidence also suggests that some infectious agents are associated with AMD. Interleukin 6 (IL-6) has also been found to be upregulated in neovascular AMD and GA, and it has been associated with GA progression (13).
[0146] Fludrocortisone acetate (9-α-fluoro-11β.17α,21-trihydroxy-4-pregnene-3,20-dione acetate, FCA) is a synthetic steroid with potent mineralocorticoid effects and high glucocorticoid activity (14), thus possessing anti-inflammatory and antiallergic properties. FCA is a mineralocorticoid receptor and glucocorticoid receptor agonist that binds to cytoplasmic receptors, translocates to the nucleus, and subsequently initiates transcription of glucocorticoid-responsive genes (such as lipocortin) to inhibit phospholipase A2. This prevents the release of arachidonic acid, a precursor of prostaglandins and leukotrienes, both of which are important mediators of proinflammatory mechanisms. In addition, the drug exerts mineralocorticoid effects on the distal tubules and collecting ducts of the kidney by inducing permeases (an enzyme that regulates the permeability of Na+ in cells), thereby enhancing Na+ reabsorption and water retention and increasing K+ and H+ excretion.
[0147] This study aimed to evaluate the safety and tolerability of a single intravitreal (IVT) dose of FCA over 6 months in patients with GA. method Study Design
[0148] This single-center, Phase 1b prospective, open-label, single-dose, dose-escalation clinical trial was conducted at a single site with nine participants between August 2019 and April 2021. All patients were followed up for six months after baseline. The trial received ethics approval prior to initiation and is registered with the Australian and New Zealand Clinical Trials Registry (available through www.anzctr .org.au; ANZCTR number: 12618001308280). An independent data and safety committee provided oversight for the clinical trial. The study adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants before participation in the study. Study Drug
[0149] Fludrocortisone acetate is formulated for intravitreal administration as a powder solution for injection to ensure long-term stability similar to other corticosteroids (15). The vial contains 10 mg of FCA powder, which is reconstituted with sterile sodium chloride solution (0.9%) according to the appropriate dose prior to injection. Study population
[0150] The inclusion criteria for the study eyes were as follows: GA secondary to AMD diagnosed using fundus autofluorescence (FAF) imaging, GA area ≥1.9 mm 2 and ≤17mm 2 Between 1 and 7 optic disc areas (DA), respectively, and best-corrected visual acuity (BCVA) of 24 letters or better using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.
[0151] Exclusion criteria were as follows: GA due to causes other than AMD, such as Stargardt disease, cone-rod dystrophy, or toxic maculopathy (eg, hydroxychloroquine maculopathy (plaquenil Patients were excluded if they had spherical equivalent refractive error indicating myopia >6 diopters or axial length >26 mm, evidence or history of exudative (wet) AMD, including evidence of retinal pigment epithelial (RPE) tears or evidence of neovascularization anywhere in the retina based on fluorescein angiography in either eye within 12 months, retinal disease that could affect visual performance or be affected by intraocular steroids, intraocular surgery (including lens exchange surgery) within 3 months prior to dosing, aphakia or posterior capsule loss, prior posterior capsule violation unless it occurred due to yttrium aluminum garnet (YAG) laser posterior capsulotomy with prior posterior chamber intraocular lens implantation and was at least 60 days prior to Day 0, glaucoma or family history of glaucoma, any contraindications to IVT injection, including current ocular or periocular infection, history of uveitis or endophthalmitis, or history of IVT injection within 12 months.
[0152] If both eyes met the criteria, the eye with the best visual acuity at the screening visit was designated as the study eye. Study plan
[0153] Comprehensive ophthalmologic evaluations were performed at each study visit, including GA area assessed by FAF imaging, BCVA, low-light BCVA (LL-BCVA), and intraocular pressure (IOP). Participants were evaluated at screening, baseline, Day 1, Day 7, Day 14, Day 28, Day 60, Day 90, and Day 150 (end of study). Blood and urine samples were collected at screening, baseline, Day 7, Day 28, and Day 150 for safety analyses.
[0154] Part 1 of the study involved one participant treated with 1 mg / 0.1 ml FCA to assess safety and tolerability. This participant was followed for 28 days before the independent Data Safety Monitoring Board (DSMB) reviewed the results. Following DSMB approval, an additional 2 participants were treated with 1 mg / 0.1 ml FCA and followed for 28 days after treatment before Part 2 began.
[0155] Part 2 involved a single dose of 2 mg / 0.1 ml FCA to a single participant with 28 days of follow-up as in Part 1. The DSMB reviewed the results prior to enrollment of the remaining 5 participants. Outcome measures
[0156] Fundus autofluorescence was captured using the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany). Assessment of GA size and progression was performed using the FAF by 2 raters (TH and EC) in a blinded manner using the Heidelberg Area Finder software version 2.6.2.0 ( Figure 1 ), a semi-automated procedure for quantifying areas of atrophy. Baseline FAF images were defined and subsequent visits were evaluated using the Area Finder software. In cases where the difference between the two scorers exceeded 20%, a third scorer (AC) evaluated the images. Areas of peripapillary atrophy were not included in the measurements. GA was defined as a well-defined hypofluorescent area on FAF due to the absence of the RPE layer on the neurosensory retina (Refs).
[0157] At each study visit, BCVA was assessed at 4 m using the ETDRS chart after subjective refraction. LL-BCVA was assessed similarly to that for neutral-density lenses. IOP was measured using Goldmann applanation tonometer. Adverse events were reported from the time the first patient received the first dose of FCA until the last visit of the last patient. Statistical analysis
[0158] Statistical analyses were performed using SPSS software version 24.0 (SPSS, Inc, Chicago, IL) and were primarily descriptive. Safety data are summarized in Results. Descriptive statistics (mean, standard deviation (SD), median, minimum, and maximum) were calculated for summary of continuous data. Paired t tests were performed to assess changes from baseline, and two-sample t tests were performed to compare changes between the two eyes.
[0159] Safety data, including vital signs, clinical safety laboratories, and adverse events, will be summarized. Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), and data will be summarized by system organ class and preferred term. result
[0160] Nine participants were enrolled in the study, and their baseline characteristics are shown in Table 3. The mean age of the participants was 79.7±6.2 years, and 55% were female. The mean baseline BCVA and LL-BCVA were 53.1±10.0 and 39.3±11.2 letters, respectively. The mean baseline area of GA was 9.50±5.7. Table 3: Baseline characteristics Baseline characteristics N=9 Age (years) mean ± SD 79.73±6.19 female 55.5% Right eye 55.5% Artificial phakic eye 55.5% BCVA (letter) mean ± SD 53.11±10.01 LLVA (letter) mean ± SD 39.33±11.21 IOP mean ± SD 13.33±3.08 <![CDATA[GA area (mm 2 ) mean ± SD]]> 9.53±5.69
[0161] An initial trial participant taking 1 mg / mL fludrocortisone acetate lost 22 letters (≥15 letters) at day 14, but the DSMB considered this to be most likely unrelated to the IP because there were no other adverse events or signs of safety issues.
[0162] One participant who received 2 mg / ml fludrocortisone acetate experienced a subconjunctival nasal hemorrhage after study day 90, which resolved after 1 week. No other adverse events were observed throughout the study.
[0163] Throughout the study, no significant increase in IOP (≥10 mmHg) was observed in any patient. The mean change in IOP on Day 150 was -0.25 mmHg (p=0.75) compared to baseline Table 4. Throughout the study, there were no significant changes in body temperature, heart rate, systolic blood pressure, or diastolic blood pressure (all p>0.05).
[0164] Four of the nine patients (44.4%) had a natural lens; no formal grading of lens opacity was performed as part of the protocol. One participant had severe lens opacity at screening that did not preclude imaging, but no participant required / underwent cataract surgery during the study period. Table 4: Changes in characteristics compared to baseline Progress of GA area
[0165] During the study period, the mean area of geographic atrophy increased in both the study eye (0.5 mm2 p=0.003) and the fellow eye (0.62 mm2 p=0.02). The change in area between the two eyes was not significant (p=0.64) Table 4. discuss
[0166] This study demonstrates that intravitreal FCA treatment is clinically safe and well tolerated in this patient population with geographic atrophy secondary to AMD. Typical side effects of intraocular steroids, including increased intraocular pressure and lens opacities, were not observed in this study. In addition, no systemic adverse events were observed in this dose-escalation study.
[0167] A recent meta-analysis of 23 studies reported that the natural progression of GA lesions in untreated eyes was 1.66 mm2 / year (16). Results from the Proxima A and B clinical trials reported increases of 2.09 mm2 / year and 1.90 mm2 / year, respectively, over the first 12 months. Another study by Schmitz-Valckenberg et al (17) reported a change of 0.88 mm2 within 6 months. Our results showed that GA progression was low in both treated eyes (0.5 mm2) and fellow eyes (0.62 mm2) during the study period, which may indicate a therapeutic effect of FCA.
[0168] Low-light visual acuity is considered a predictor of visual loss in patients with GA, and it can detect changes in central function earlier than standard VA assessment (18–20). Our results, which showed that LLVA did not worsen during the study period, may be considered promising and deserve more detailed investigation in a larger group.
[0169] Previous studies evaluating intravitreal glucocorticoid treatment have found improvements in blood-retinal barrier (BRB) function (21, 22). These results are consistent with preclinical studies of FCA in vitro and in vivo using AMD mouse models (23). In these experiments, FCA was found to have potent anti-inflammatory effects and neuroprotective properties in AMD models.
[0170] Previous clinical studies have reported that monocular treatment can affect the fellow eye (24-26), which means that comparisons of measurements between the treated and fellow eyes are not valid controls, and population norms are the most useful comparisons. Given that both the treated and fellow eyes showed slower rates of progression compared with previous reports, it is possible that similar sympathetic responses may occur in the untreated eye.
[0171] Maddess et al. recently reported a significant correlation between peripheral macular area in treated and untreated nAMD eyes receiving anti-VEGF therapy based on monthly assessments over 15 months (see Rai et al. in press). Therefore, we believe that the results of our study may indicate that intraocular injection of FCA at 2 mg / ml may reduce the rate of progression of GA, but a larger cohort over a longer time frame is needed to formally draw such a conclusion.
[0172] Limitations of this study include the small sample size and lack of formal lens grading, both of which were considered unimportant for the primary objective of this safety study. Another limitation of this study is the small sample size and short study duration. Strengths of this study include its prospective design.
[0173] In conclusion, the data suggest that intravitreal FCA injection is clinically safe and well tolerated. FCA treatment does not increase IOP and has good indications in terms of GA lesion growth and LLVA. Further long-term studies (with larger sample size and multiple dose schedules) may help evaluate the efficacy of FCA in slowing down GA progression.
[0174] Although the present invention has been described in conjunction with specific embodiments, it will be appreciated that the present invention is capable of further modifications. This application is intended to cover any variation, use or modification of the present invention that generally follows the principles of the present invention, and includes any variation, use or modification of the basic features that are applicable to the above description that are known or customary practices in the field to which the present invention belongs, which are out of the present disclosure.
[0175] Since the present invention can be implemented in various forms without departing from the spirit of the basic characteristics of the present invention, it should be understood that unless otherwise specified, the above embodiments do not limit the present invention, but should be widely interpreted within the spirit and scope of the present invention defined in the appended claims. The described embodiments should be considered in all respects to be illustrative only and not restrictive.
[0176] Various modifications and equivalent arrangements are intended to be included within the spirit and scope of the present invention and the appended claims. Therefore, the specific embodiments should be understood as illustrating many ways in which these principles of the present invention can be implemented. In the appended claims, means-plus-function clauses are intended to cover structures that perform the defined function, including not only structural equivalents, but also equivalent structures.
[0177] When a Markush group or other grouping is used herein, all individual members of the group and all possible combinations and subcombinations of the group members are intended to be individually included in the disclosure. Unless otherwise stated, every combination of components described or exemplified herein can be used to practice the invention.
[0178] Whenever a range is given in the specification, such as a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, as well as all individual values contained in the given range, are intended to be included in the disclosure. It should be understood that any subrange included in the description herein or individual values within a range or subrange may be excluded from the claims herein.
[0179] As used herein, "comprising" is synonymous with "including", "containing" or "characterized by", and is inclusive or open-ended, and does not exclude additional, unlisted elements or method steps. "Consisting of..." as used herein does not include any element, step or ingredient not specified in the claim element. "Mainly consisting of..." as used herein does not exclude materials or steps that do not substantially affect the basic and novel features of the claim. The broad term "comprising" is intended to encompass the narrower "essentially consisting of..." and the even narrower "consisting of...". Therefore, any expression of the phrase "comprising one or more claim elements" (e.g., "comprising A") herein is intended to include the narrower ones, such as "essentially consisting of A" and "consisting of A". Therefore, the broader word "comprising" is intended to provide specific support for each use of "essentially consisting of..." or "consisting of..." herein. The invention exemplarily described herein can be appropriately practiced in the absence of any element or elements, limitations or limitations not specifically disclosed herein.
[0180] Those of ordinary skill in the art will recognize that, in addition to the materials and methods specifically illustrated, other materials and methods may be employed in the practice of the present invention without resorting to excessive experimentation. The present invention is intended to encompass all functional equivalents known in the art for any such materials and methods. The terms and expressions employed are used only as descriptive terms, not restrictive terms, and the use of these terms and expressions is not intended to exclude any features or portions thereof that are equivalent to those shown and described, but it should be recognized that various modifications may be made within the scope of the present invention. Therefore, it should be understood that although the present invention has been specifically disclosed by embodiments, preferred embodiments, and optional features, those skilled in the art may modify and change the concepts disclosed herein, and such modifications and changes are considered to be within the scope of the present invention as defined by the appended claims.
[0181] Each reference cited herein is incorporated in its entirety. These references may provide sources of materials, alternative materials, method details, and other uses of the present invention. References 1. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-relatedmaculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995; 102(10): 1450-60. 2.Klein R,Klein BE,Linton KL.Prevalence of age-relatedmaculopathy.The Beaver Dam Eye Study.Ophthalmology.1992;99(6):933-43. 3.Klein R,Klein BE,Tomany SC,Moss SE.Ten-year incidence of age-related maculopathy and smoking and drinking:the Beaver Dam EyeStudy.American journal of epidemiology.2002;156(7):589-98. 4.Michalska- K,Kabiesz A,Nowak M, D.Age relatedmacular degeneration-challenge for future:Pathogenesis and new perspectivesfor the treatment.European Geriatric Medicine.2015;6(1):69-75. 5.Holz FG,Strauss EC,Schmitz-Valckenberg S,van Lookeren CampagneM.Geographic atrophy:clinical features and potential therapeuticapproaches.Ophthalmology.2014;121(5):1079-91. 6.Coleman HR,Chan CC,Ferris FL,3rd,Chew EY.Age-related maculardegeneration.Lancet(London,England).2008;372(9652):1835-45. 7.Klein R,Klein BE,Knudtson MD,Meuer SM,Swift M,Gangnon RE.Fifteen-year cumulative incidence of age-related macular degeneration:the Beaver DamEye Study.Ophthalmology.2007;114(2):253-62. 8.Klein R,Cruickshanks KJ,Nash SD,Krantz EM,Nieto FJ,Huang GH,etal.The prevalence of age-related macular degeneration and associated riskfactors.Archives of ophthalmology(Chicago,Ill:1960).2010;128(6):750-8.9.ChongEW,Wong TY,Kreis AJ,Simpson JA,Guymer RH.Dietaryantioxidants and primaryprevention of age related macular degeneration:systematic review and meta-analysis.BMJ(Clinical research ed).2007;335(7623):755. 10.Ding X,Patel M,Chan CC.Molecular pathology of age-related maculardegeneration.Progress in retinal and eye research.2009;28(1):1-18. 11.Dastgheib K,Green WR.Granulomatous reaction to Bruch's membrane inage-related macular degeneration.Archives of ophthalmology(Chicago,Ill:1960).1994;112(6):813-8. 12.Penfold PL,Wong JG,Gyory J,Billson FA.Effects of triamcinoloneacetonide on microglial morphology and quantitative expression of MHC-II inexudative age-related macular degeneration.Clinical&experimentalophthalmology.2001;29(3):188-92. 13.Krogh Nielsen M,Subhi Y,Molbech CR,Falk MK,Nissen MH, TL.Systemic Levels of Interleukin-6 Correlate With Progression Rate ofGeographic Atrophy Secondary to Age-Related MacularDegeneration.InvestOphthalmol Vis Sci.2019;60(1):202-8. 14.Gomez-Sanchez CE,Kirk DN,Farrant RD,Milewich L.18-substitutedsteroids:Synthesis of 18-hydroxycortisol(11β,17α,18,21-tetrahydroxy-4-pregnene-3,20-dione)and 18-hydroxycortisone(17α,18,21-trihydroxy-4-pregnene-3,11,20-trione).Journal of Steroid Biochemistry.1985;22(1):141-6. 15.Tao Y,Jonas JB.Intravitreal triamcinolone.Ophthalmologica.2011;225(1):1-20. 16.Wang J,Ying GS.Growth Rate of Geographic Atrophy Secondary to Age-Related Macular Degeneration:A Meta-Analysis of Natural History Studies andImplications for Designing Future Trials.Ophthalmic Res.2021;64(2):205-15. 17.Schmitz-Valckenberg S,Sahel JA,Danis R,Fleckenstein M,Jaffe GJ,Wolf S,et al.Natural History of Geographic Atrophy Progression Secondary toAge-Related Macular Degeneration(Geographic Atrophy Progression Study).Ophthalmology.2016;123(2):361-8. 18.Wood LJ,Jolly JK,Buckley TM,Josan AS,MacLaren RE.Low luminancevisual acuity as a clinical measure and clinical trial outcome measure:ascoping review.Ophthalmic Physiol Opt.2021;41(2):213-23. 19.Sunness JS,Rubin GS,Broman A,Applegate CA,Bressler NM,HawkinsBS.Low luminance visual dysfunction as a predictor of subsequent visualacuity loss from geographic atrophy in age-related maculardegeneration.Ophthalmology.2008;115(9):1480-8,8.e1-2. 20.Wu Z,Ayton LN,Luu CD,Guymer RH.Longitudinal changes inmicroperimetry and low luminance visual acuity in age-related maculardegeneration.JAMA Ophthalmol.2015;133(4):442-8. 21.van der Wijk AE,Canning P,van Heijningen RP,Vogels IMC,van NoordenCJF,Klaassen I,et al.Glucocorticoids exert differential effects on theendothelium in an in vitro model of the blood-retinal barrier.ActaOphthalmol.2019;97(2):214-24. 22.Lee JY,Eun CK,Kim YW,Kim HJ,Jung YJ,Jae SY,et al.The steroideffect on the blood-ocular barrier change induced by triolein emulsion asseen on contrast-enhanced MR images.Korean J Radiol.2008;9(3):205-11. 23.Racic T,Chang A,Fernando N,Brandli A,Natoli R,Penfold P,etal.Anti-inflammatory and neuroprotective properties of the corticosteroidfludrocortisone in retinal degeneration.Exp Eye Res.2021;212:108765. 24.Aghayeva FA,Chronopoulos P,Schuster AK,Pfeiffer N,HoffmannEM.Inter-eye relationship of intraocular pressure change after unilateraltrabeculectomy,filtering canaloplasty,or PreserFlo TM microshuntimplantation.Graefes Arch Clin Exp Ophthalmol.2021;259(10):3045-53. 25.Gibbens MV.Sympathetic influences on the consensual ophthalmotonicreaction.Br J Ophthalmol.1988;72(10):750-3. 26.Rao HL,Senthil S,Garudadri CS.Contralateral intraocular pressurelowering effect of prostaglandin analogues.Indian J Ophthalmol.2014;62(5):575-9.
Claims
1. A method for treating a subject having a retinal ocular disorder refractory to anti-VEGF therapy, the method comprising administering to the subject a therapeutically effective amount of one or more steroids following anti-VEGF therapy, thereby treating the retinal ocular disorder.
2. A method for treating a subject suffering from a retinal ocular disorder refractory to anti-VEGF treatment, the method comprising administering to the subject a therapeutically effective amount of one or more compounds capable of modulating the activity of a steroid receptor, preferably a glucocorticoid receptor and / or a mineralocorticoid receptor, to treat the retinal ocular disorder following anti-VEGF treatment.
3. A method for treating a subject having a retinal ocular disorder refractory to anti-VEGF therapy, the method comprising administering to the subject, following anti-VEGF therapy, at a concentration and dosage sufficient to improve the retinal ocular disorder: (a) a therapeutically acceptable formulation of a steroid suitable for delivery to the eye, and (b) at least one second therapeutically active compound.
4. The method of claim 1 or 3, wherein the steroid is one or more mineralocorticoids or glucocorticoids or therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates thereof.
5. The method of claim 4, wherein the one or more mineralocorticoids and / or multiple glucocorticoids or therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates thereof comprise one or more dual-acting compounds, wherein each dual-acting compound is capable of modulating the activity of both a mineralocorticoid receptor and a glucocorticoid receptor.
6. The method according to any one of claims 1 to 5, wherein the one or more mineralocorticoids or therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates thereof comprise one or more of: 11-deoxycortisone (11-DC); fludrocortisone; fludrocortisone acetate (FA); fludrocortisone acetone; deoxycorticosterone acetate (DA); deoxycorticosterone (DS); or aldosterone; or therapeutically active analogs, derivatives, homologues, pharmaceutically acceptable salts or conjugates thereof.
7. according to the method described in any one in claim 1 to 6, wherein said one or more glucocorticoids or its therapeutically active analog, derivative, homologue, pharmaceutically acceptable salt or conjugate can comprise one or more of the following: Cortisol, cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, beclomethasone, fluocinolone acetonide or its therapeutically active analog, derivative, homologue, pharmaceutically acceptable salt or conjugate.
8. The method of claim 5, wherein the dual-acting compound comprises one or more of: triamcinolone; triamcinolone acetonide; cortisol; cortisone; prednisone; prednisolone; methylprednisolone; fludrocortisone; fludrocortisone acetate; fludrocortisone acetonide; or a therapeutically active analog, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof.
9. according to the method described in any one in claim 1 to 8, wherein said one or more mineralocorticoids or one or more glucocorticoids or its therapeutic activity analog, derivative, homologue, pharmaceutically acceptable salt or conjugate comprise fludrocortisone or its therapeutic activity analog, derivative, homologue, pharmaceutically acceptable salt or conjugate, optionally wherein said therapeutic activity analog, derivative, homologue, pharmaceutically acceptable salt or conjugate can comprise fludrocortisone acetate and fludrocortisone acetonide.
10. according to the method described in any one in claim 1 to 9, wherein said one or more mineralocorticoids and / or one or more glucocorticoids or its therapeutically active analog, derivative, homologue, pharmaceutically acceptable salt or conjugate comprise triamcinolone acetonide or its therapeutically active analog, derivative, homologue, pharmaceutically acceptable salt or conjugate.
11. The method according to any one of claims 1 to 10, wherein the retinal eye disorder is macular edema (ME), such as diabetic macular edema (DME), or age-related macular degeneration (AMD), including wet AMD or dry AMD.
12. The method according to any one of claims 1 to 11, wherein the retinal eye disorder comprises: Exudative eye conditions; Posterior ocular conditions; Macular degeneration, including age-related macular degeneration (AMD), including dry (geographic atrophy) and wet (choroidal neovascularization (CNV)); macular edema (ME), including diabetic macular edema (DME), angiographic cystoid macular edema, cystoid macular edema (CMO); diabetic retinopathy (DR), including proliferative diabetic retinopathy (PDR); and retinal vein occlusion, including central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO); maculopathy, including age-related maculopathy (ARM); exudative eye diseases or conditions; retinal pigment epithelial detachment (PED); various forms of age-related macular degeneration; diabetic eye diseases or conditions, including diabetic retinopathy; corneal neovascularization; cyclitis; Hippel-Lindl disease; retinopathy of prematurity (also known as retrolental fibroplasia); pterygium; histoplasmosis; iris neovascularization; glaucoma; glaucoma-related neovascularization; Pucher's retinopathy; elevated intraocular pressure; macular edema; Coats' disease; uveitis, including anterior uveitis; Sjögren's syndrome; inherited disorders associated with increased extracellular lipid storage / accumulation; juvenile macular degeneration; ocular allergies and ocular tumors.
13. The method of claim 12, wherein the eye disease or condition comprises a posterior ocular disease or condition, including an exudative posterior ocular disease or condition, optionally comprising an eye disease or condition involving the retina, macula and / or fovea of the posterior region of the eye.
14. The method of any one of claims 1 to 13, wherein the ocular disease or condition comprises dry AMD, optionally early AMD and geographic atrophy (GA), other than exudative AMD.
15. The method according to any one of claims 1 to 14, wherein the eye disease and / or disorder is a diabetic eye disease and / or disorder.
16. The method of any one of claims 1 to 15, wherein the therapeutically effective amount comprises a range of about 0.01 wt% to about 10 wt%, optionally a range of about 0.025 wt% to about 2.5 wt%.
17. The method of any one of claims 1 to 16, wherein the one or more steroids are injected into the eye, optionally wherein the injection comprises a suprachoroidal injection.
18. The method according to any one of claims 1 to 17, wherein the one or more steroids are provided in a unit dose formulation, optionally, the unit dose formulation is provided in a pre-filled syringe, optionally, the pre-filled syringe comprises two barrels.
19. A method according to any one of claims 1 to 18, comprising one or more pharmaceutically acceptable carriers, diluents or excipients, such as one or more surfactants or wetting agents.
20. The method of claim 19, wherein the one or more pharmaceutically acceptable carriers comprises cannabis, cannabis oil, or a pharmaceutically effective cannabis or cannabis oil extract, optionally wherein the carrier comprises cannabis oil containing about 80% to 90% balanced omega fatty acids.
21. A method according to claim 20, wherein the cannabis, cannabis oil or pharmaceutically effective extract is used or used as a carrier or delivery vehicle for one or more steroids.
